Floatz logo

T-Vec

Human Papillomavirus-Related Malignant Neoplasm

PfizerPhase 1Dormant
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
22/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Human Papillomavirus-Related Malignant Neoplasm cohort.

Asset / SponsorPhaseRating
TTI-621
Pfizer
Phase 1CC
Pegylated Interferon-Alpha-2A
Pfizer
Phase 1CC

Same molecule, other indications

T-Vec is also rated in:

melanomaDormant
CC
Indicative ·
46 / 100
View asset →
mycosis fungoidesDormant
C
Indicative ·
37 / 100
View asset →
cutaneous neuroendocrine carcinomaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →